This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ZEUS was a randomized phase 3 parallel-group trial evaluating two coronary stent strategies in patients with coronary artery disease.
| Feature | ZEUS |
|---|---|
| Clinical condition | Coronary Artery Disease |
| Design | Randomized, parallel, single masked |
| Primary purpose | Treatment |
| Interventions | Bare metal stent implantation; zotarolimus eluting stent |
| Study start | 2011-06 |
| Primary completion | 2012-09 |
2. Clinical Question
Population
Patients with coronary artery disease enrolled in the ZEUS randomized clinical trial.
Intervention
Zotarolimus eluting stent implantation.
Comparator
Bare metal stent implantation.
Primary question
How do major adverse cardiovascular events differ between the two randomized stent strategies at 12 months?
3. Trial Design
Randomized
Parallel assignment
Single masking
Two device-treatment groups
Bare metal stent implantation
Comparator device strategy.
Zotarolimus eluting stent
Investigational device strategy.
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| MACE | Major adverse cardiovascular events including death for any cause, non-fatal myocardial infarction or target vessel revascularisation | 12 months |
5. Planned Analysis
The registry identifies MACE as the primary endpoint but does not report posted statistical analyses or trial results on ClinicalTrials.gov.
A composite cardiovascular endpoint such as MACE is typically analyzed by comparing the occurrence of events between randomized groups. Depending on the prespecified statistical analysis plan, this may involve event-rate comparisons, time-to-event methods, or other methods appropriate for the endpoint definition.
6. Statistical Methodology
Composite endpoints
MACE combines multiple clinically important events into a single outcome. This can improve statistical efficiency by increasing the number of observed events, but interpretation requires understanding which components contribute most strongly to the composite.
Randomization and treatment comparison
Randomization creates comparable treatment groups on average and provides the basis for estimating differences between device strategies. The primary comparison should remain aligned with the randomized assignment.
Event-time analysis
For cardiovascular outcomes, time until the first occurrence of an event is often important. Survival-analysis approaches account for different follow-up durations and patients who do not experience an event during observation.
7. Statistical Methods Explained
Why use a composite endpoint such as MACE?
A composite endpoint combines several clinically relevant outcomes. The interpretation depends on the individual components, because frequent but less severe components can influence the overall result more than rare severe events.
What does randomization contribute statistically?
Randomization reduces systematic differences between groups at baseline, allowing differences in outcomes to be attributed more directly to the assigned intervention.
Why is follow-up time important?
Cardiovascular event risk changes over time. Analyses that incorporate timing of events provide more information than simply counting whether an event occurred.
What does a confidence interval show?
A confidence interval describes uncertainty around an estimated treatment comparison. Narrower intervals generally indicate greater statistical precision than wider intervals.
Why should MACE components be examined separately?
A composite outcome can conceal differences between components. Death, myocardial infarction, and target vessel revascularisation may have different clinical importance and frequency.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or numerical trial results.
- The registry does not report component-specific MACE results, event counts, or effect estimates.
- The available record does not provide subgroup analyses, missing-data methods, multiplicity adjustments, or interim analysis details.
- Interpretation of composite cardiovascular endpoints requires attention to the contribution of each component outcome.
9. Why This Trial Matters Statistically
ZEUS illustrates several important concepts in clinical trial methodology, including randomized device comparisons, composite cardiovascular endpoints, and the statistical challenges of evaluating multiple types of clinical events within a single outcome definition.
| Concept | Application |
|---|---|
| Randomization | Comparison of two assigned device strategies |
| Parallel design | Patients remain in their randomized treatment groups |
| Composite endpoint | MACE combines multiple cardiovascular outcomes |
| Time-to-event analysis | Useful framework for cardiovascular outcomes |